HoldsUp

Huberman Lab · 2025-11-24 · Andrew Huberman (host), Thaïs Aliabadi

Female Hormone Health, PCOS, Endometriosis, Fertility & Breast Cancer | Dr. Thaïs Aliabadi

100 research-tied claims examined: 2 contradicted 9 overstated 16 context 70 supported 3 unverified

70 Supported by research
0:00:02Andrew Huberman (host)supportedhigh

Cataracts are the most common cause of blindness.

"Most common form of blindness." (said at 0:00:02)

Global epidemiological data from large systematic reviews and meta-analyses (including the Global Burden of Disease Study and Vision Loss Expert Group) confirm that cataract is the leading cause of blindness worldwide, responsible for an estimated 15.2 million cases of blindness in adults aged 50 years and older in 2020.

0:04:03Thaïs Aliabadisupportedmoderate

Polycystic ovary syndrome (PCOS) and endometriosis are the leading causes of female infertility worldwide.

"I want to shed light on these topics, especially endometriosis and PCOS, because they're the top leading causes of infertility on this planet." (said at 0:04:03)

Epidemiological data and clinical reviews confirm that polycystic ovary syndrome (PCOS) and endometriosis are among the leading identifiable causes of female infertility globally. Ovulatory disorders account for approximately 25% of all infertility cases, with PCOS responsible for roughly 70% to 80% of anovulatory infertility. Along with endometriosis and tubal factors, they represent the primary gynecological conditions driving female infertility worldwide.

0:05:00Thaïs Aliabadisupportedmoderate

Women are born with millions of eggs, do not generate new eggs after birth, and deplete their reserve to approximately 1,000 eggs at menopause.

"So we are born with a certain number of eggs, millions of them. And we don't make more eggs after we're born. And as we go through life, we start losing these eggs until at about menopause, we have about a thousand of them left." (said at 0:05:00)

The speaker accurately describes the established biological model of the human ovarian reserve: females are endowed with a non-renewing pool of germ cells/primordial follicles during prenatal development (typically estimated between hundreds of thousands to 1–2 million at birth), do not generate new oocytes postnatally, and experience continuous follicular atresia throughout life until reaching a critical threshold of approximately 1,000 follicles around the time of natural menopause.

0:07:45Thaïs Aliabadisupportedhigh

Anti-Müllerian hormone (AMH) blood testing measures ovarian egg count/reserve.

"Egg count, AMH, anti-Müllerian hormone, is a simple blood test." (said at 0:07:45)

Anti-Müllerian hormone (AMH) is produced by the granulosa cells of growing ovarian follicles. Serum AMH testing is a simple blood test that correlates strongly with the size of the primordial follicle pool and antral follicle count, making it the standard and most validated clinical biomarker for assessing ovarian reserve (egg supply). It should be noted that while AMH reflects egg quantity and predicted response to ovarian stimulation in assisted reproduction, it does not measure egg quality or natural monthly fertility (fecundability).

0:12:15Andrew Huberman (host)supportedmoderate

PFAS chemicals are linked to hormone disruption, gut microbiome disruption, and fertility issues.

"these PFAS or forever chemicals like Teflon have been linked to major health issues such as hormone disruption, gut microbiome disruption, fertility issues, and many other health problems." (said at 0:12:15)

The host's statement that per- and polyfluoroalkyl substances (PFAS) are linked to hormone disruption, gut microbiome disruption, and fertility issues is supported by published observational human studies and mechanistic/toxicological reviews. PFAS exposure is well-established in toxicological literature as an endocrine-disrupting chemical class associated with reproductive toxicity, fertility impairments, and perturbations to gut microbiota diversity and community composition.

0:15:24Thaïs Aliabadisupportedhigh

PCOS is the most common hormone disorder in women of reproductive age.

"So PCOS is the most common hormone disorder in women in the reproductive age." (said at 0:15:24)

The speaker's statement that polycystic ovary syndrome (PCOS) is the most common hormone/endocrine disorder in women of reproductive age is well-established in the medical literature, epidemiological consensus, and international clinical guidelines. Depending on diagnostic criteria (such as the Rotterdam criteria), PCOS affects an estimated 4% to 20% of women in their reproductive years.

0:16:18Thaïs Aliabadisupportedhigh

The diagnostic criteria for PCOS require meeting at least two out of three criteria: hyperandrogenism symptoms/elevated androgens, ovulatory dysfunction/irregular periods, and polycystic ovarian morphology on ultrasound or elevated AMH.

"So when it comes to diagnosing PCOS, you need to meet two out of three criteria. The first one being symptoms of high testosterone or high androgens... Number two is basically ovulation dysfunction... And number three is PCOS-looking ovaries on ultrasound... However, in 2023, they added another criteria to this third criteria, which is elevated egg count or elevated AMH." (said at 0:16:18)

The speaker accurately describes the Rotterdam diagnostic criteria for polycystic ovary syndrome (PCOS) and the key update from the 2023 International Evidence-based Guideline. Diagnosis in adult women requires meeting at least two of the three cardinal features: clinical/biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology (PCOM). The 2023 international guideline officially integrated serum anti-Müllerian hormone (AMH) as an alternative marker to pelvic ultrasound for determining PCOM in adults.

0:17:20Thaïs Aliabadisupportedhigh

In PCOS, a polycystic ovary appearance on ultrasound is characterized by seeing 20 or more follicles arranged in a 'string of pearls' pattern.

"When you see almost like 20-plus follicles in the ovary, and these are follicles, they look like a string of pearls. It's very specific to PCOS." (said at 0:17:20)

Updated international consensus guidelines and diagnostic meta-analyses establish that polycystic ovarian morphology (PCOM) on transvaginal ultrasound using modern high-frequency transducers is defined by a threshold of ≥20 follicles per ovary (FNPO) measuring 2–9 mm (or ≥25 follicles depending on transducer/guideline threshold) and/or an increased ovarian volume (≥10 mL). These immature antral follicles characteristically arrange peripherally in the ovary around an expanded stroma, creating the classic 'string of pearls' appearance. Diagnostic meta-analyses demonstrate high diagnostic accuracy and specificity (pooled specificity ~91%) for FNPO in adult women.

0:18:55Thaïs Aliabadisupportedhigh

High testosterone levels in blood are not required to diagnose PCOS if clinical symptoms of hyperandrogenism are present.

"Now, let me tell you, you do not need to have a high testosterone in the blood to get the diagnosis of PCOS. If you do, great. Then you qualify for that high testosterone symptom or in blood. But you do not need to have a high testosterone in your blood." (said at 0:18:55)

Under established international diagnostic criteria for polycystic ovary syndrome (the Rotterdam criteria and the International Evidence-based PCOS Guidelines), hyperandrogenism can be established either clinically (such as through hirsutism, alopecia, or acne) or biochemically (elevated circulating androgens such as testosterone). An individual does not need elevated blood testosterone levels to receive a PCOS diagnosis if clinical signs of hyperandrogenism (or other diagnostic criteria such as ovulatory dysfunction and polycystic ovarian morphology) are present.

0:22:45Thaïs Aliabadisupportedhigh

Ovarian morphology on ultrasound and AMH levels should not be used as diagnostic criteria for PCOS in teenagers.

"So actually the PCOS morphology is not used for teenagers. For teenagers to get the diagnosis of PCOS, they need to have criteria one, which is the irregular period, and criteria two, which is the high androgen symptoms. You do not use the AMH or PCOS morphology on ultrasound as a diagnostic criteria." (said at 0:22:45)

The speaker's statement accurately reflects the International Evidence-Based Guidelines for the Assessment and Management of Polycystic Ovary Syndrome (PCOS). In adolescents (typically defined within 8 years post-menarche), normal pubertal ovarian development frequently exhibits multifollicular morphology and elevated anti-Müllerian hormone (AMH) levels, leading to high rates of false positives. Consequently, international guidelines mandate that a PCOS diagnosis in adolescents requires both irregular menstrual cycles and evidence of hyperandrogenism (clinical and/or biochemical), explicitly stating that pelvic ultrasound (polycystic ovarian morphology) and serum AMH levels should not be used as diagnostic criteria.

0:28:40Thaïs Aliabadisupportedhigh

PCOS has four distinct phenotypes.

"The problem with PCOS is there are four different phenotypes of PCOS. That's why it's so confusing for doctors to diagnose PCOS." (said at 0:28:40)

Under the established Rotterdam diagnostic consensus and international PCOS guidelines, polycystic ovary syndrome is formally classified into four distinct phenotypes based on combinations of its three core diagnostic features (hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology): Phenotype A (all three features), Phenotype B (hyperandrogenism and ovulatory dysfunction), Phenotype C (hyperandrogenism and polycystic ovaries), and Phenotype D (ovulatory dysfunction and polycystic ovaries).

0:18:15Thaïs Aliabadisupportedhigh

In 2023, updated international clinical guidelines added elevated anti-Müllerian hormone (AMH) as an alternative diagnostic marker to polycystic ovarian morphology on ultrasound for PCOS.

"However, in 2023, they added another criteria to this third criteria, which is elevated egg count or elevated AMH. So, women who have very high AMH, that is a telltale sign for PCOS." (said at 0:18:15)

The 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (PCOS) updated the Rotterdam diagnostic criteria by incorporating serum anti-Müllerian hormone (AMH) as an alternative diagnostic marker to ultrasound-detected polycystic ovarian morphology (PCOM) in adult women.

0:28:35Thaïs Aliabadisupportedmoderate

Postpartum hair loss is temporary and typically resolves within 9 to 12 months.

"I'm not talking about the hair loss that you get postpartum. You know what? That's transitional and it recovers in like 9 to 12 months." (said at 0:28:35)

Postpartum hair loss (postpartum telogen effluvium) is a transitional condition caused by the rapid drop in pregnancy-related hormones following delivery, shifting hair follicles into the telogen (resting/shedding) phase. Observational studies demonstrate that shedding typically starts around 2 to 3 months postpartum, peaks around 5 months, and spontaneously resolves on average within 8 to 12 months (or by the end of the first postpartum year), matching the speaker's timeline.

0:37:27Thaïs Aliabadisupportedmoderate

In PCOS, rapid GnRH pulsatility from the hypothalamus shifts gonadotropin balance so that LH is approximately double the level of FSH, stimulating ovarian theca cells to overproduce androgens.

"The GnRH, remember that secretes from the hypothalamus, it starts pulsating super fast. By doing that, it shifts the FSH-LH balance, so FSH goes down and LH goes up. LH stimulates these cells in the ovary. I don't know if you remember, the theca cells in the ovary, and they start pumping androgens out, right?" (said at 0:37:27)

The speaker accurately describes the established neuroendocrine pathophysiology of polycystic ovary syndrome (PCOS). In women with PCOS, hypothalamic GnRH pulse frequency is persistently elevated. Faster GnRH pulsatility preferentially stimulates the pituitary synthesis and secretion of luteinizing hormone (LH) over follicle-stimulating hormone (FSH), elevating circulating LH concentrations and increasing the LH-to-FSH ratio. Elevated LH acts directly on ovarian theca cells, stimulating steroidogenesis and excessive production of androgens.

0:41:49Thaïs Aliabadisupportedmoderate

Approximately 80% of individuals with PCOS have insulin resistance.

"PCOS patients, 80% of them have insulin resistance. It's not their fault. They're born that way." (said at 0:41:49)

Published literature and clinical studies using gold-standard euglycemic-hyperinsulinemic clamp techniques indicate that insulin resistance affects approximately 75% to 95% of women with polycystic ovary syndrome (PCOS) (including ~75% of lean women and ~95% of overweight women with PCOS), with standard review literature citing overall prevalence rates ranging from 50% to 80%.

0:44:06Thaïs Aliabadisupportedhigh

High insulin levels in PCOS inhibit hepatic production of sex hormone-binding globulin (SHBG), thereby increasing circulating free androgen and testosterone concentrations.

"The other thing insulin does, it blocks the liver from secreting sex hormone-binding globulin. If you do a blood test on a PCOS patient, a lot of them, the sex hormone-binding globulin is low. Sex hormone-binding globulin is a protein in the blood that grabs free testosterone from our blood, right? When the levels go down because of high insulin, our free androgens and testosterone go up." (said at 0:44:06)

The speaker's statement accurately reflects established endocrine physiology and pathophysiology in polycystic ovary syndrome (PCOS). In PCOS, compensatory hyperinsulinemia secondary to insulin resistance suppresses hepatic production of sex hormone-binding globulin (SHBG). Because SHBG binds testosterone and other sex steroids in circulation, reduced SHBG concentrations lead to an increased fraction of free (bioavailable) testosterone and circulating androgens.

0:45:20Thaïs Aliabadisupportedmoderate

Visceral fat releases inflammatory cytokines that worsen insulin resistance and stimulate ovarian androgen production.

"Visceral fat actually releases cytokines, inflammatory factors that increase the inflammation. Inflammation makes our insulin resistance worse, and inflammation, which is the next pillar, stimulates our ovaries to secrete more androgens." (said at 0:45:20)

The speaker's statement accurately describes the established pathophysiological links in metabolic syndrome and polycystic ovary syndrome (PCOS). Visceral adipose tissue secretes pro-inflammatory cytokines (such as TNF-alpha and IL-6) that exacerbate systemic insulin resistance. In turn, inflammatory mediators and associated hyperinsulinemia have been shown in clinical and in vitro mechanistic studies to directly upregulate theca cell steroidogenic enzymes, stimulating ovarian androgen production and sustaining a vicious metabolic cycle.

0:54:01Thaïs Aliabadisupportedhigh

In 2023, the diagnostic criteria for PCOS were updated to allow elevated anti-Müllerian hormone (AMH) as an alternative to polycystic ovarian morphology on ultrasound.

"So these patients, that's why in 2023 they changed that second criteria—the PCOS ovaries to elevated or elevated AMH." (said at 0:54:01)

The 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (PCOS) updated the diagnostic algorithm to include serum anti-Müllerian hormone (AMH) levels as an alternative marker to ultrasound assessment of polycystic ovarian morphology (PCOM) in adult individuals.

0:54:29Thaïs Aliabadisupportedmoderate

A normal AMH level for women in their 20s and 30s is up to 6 ng/mL, whereas for women in their 40s it is typically less than 1 ng/mL.

"So I would say up to six is normal... Less than one." (said at 0:54:29)

Large population-based and cohort studies evaluating age-specific anti-Müllerian hormone (AMH) reference ranges confirm that normal median AMH concentrations in healthy women in their 20s and 30s generally range between approximately 2 and 6 ng/mL. With advancing age, AMH declines progressively; by age 40–45, median levels typically fall below 1.0 ng/mL (e.g., median 1.35 ng/mL at age 40 declining to 0.33 ng/mL at age 45), aligning closely with the speaker's rule of thumb.

0:57:38Thaïs Aliabadisupportedmoderate

In IVF, producing one viable embryo requires approximately 3 eggs at age 25 to 28, but requires roughly 10 to 15 eggs at age 40.

"I can tell you if at age 25, 28, every three eggs make one embryo, at 40, you might need 10 to 15 eggs to make one embryo." (said at 0:57:38)

The speaker's estimate accurately reflects clinical reproductive medicine and IVF data regarding oocyte-to-euploid embryo ratios by maternal age. Large cohort studies and predictive models (such as the ART calculator and PGT-A cohort studies) demonstrate that younger women (<30-35 years) require approximately 3 to 5 mature oocytes to yield one euploid (chromosomally normal/viable) blastocyst, whereas women aged 40 and older require roughly 10 to 15 or more mature oocytes per euploid embryo due to age-related increases in embryonic aneuploidy and declining blastulation rates.

0:58:38Thaïs Aliabadisupportedmoderate

Approximately 50% of counties in the United States do not have a practicing OB/GYN.

"And let me tell you, 50% of counties in this country don't have an OB/GYN." (said at 0:58:38)

The speaker's statement that approximately 50% of counties in the United States lack an OB/GYN is supported by national healthcare workforce analyses and demographic studies, which show that nearly half (approximately 49-50%) of all U.S. counties have no practicing obstetrician-gynecologists, disproportionately affecting rural and nonmetropolitan areas.

0:36:32Thaïs Aliabadisupportedhigh

During the first 12 weeks of pregnancy, the corpus luteum releases progesterone to support endometrial implantation and maintain early pregnancy.

"And usually that cyst, the corpus luteal cyst during the first 12 weeks of pregnancy, is helping release the progesterone to help the pregnancy really stick to that wall of the uterus, in simple terms." (said at 0:36:32)

The speaker's statement accurately summarizes the physiological role of the corpus luteum during early pregnancy. Following fertilization, human chorionic gonadotropin (hCG) rescues the corpus luteum, which secretes progesterone essential for endometrial receptivity, implantation, and early pregnancy maintenance. The corpus luteum serves as the primary source of progesterone during the early first trimester until the luteoplacental shift occurs (initiating around 7–9 weeks and completing by approximately 10–12 weeks of gestation), after which the placenta takes over the bulk of progesterone production.

1:03:51Thaïs Aliabadisupportedhigh

Birth control pills stimulate sex hormone-binding globulin (SHBG) production, which binds circulating testosterone and helps relieve symptoms of PCOS.

"Birth control pills stimulate that sex hormone binding globulin that starts grabbing the testosterone and helps with their symptoms. That's why if you go to the doctor and you say, "I have acne," they're like, "Birth control." "I have hair loss," "Birth control." "My periods are irregular," "Birth control." We use it for everything, right? But it does work to treat the symptoms of PCOS." (said at 1:03:51)

Combined oral contraceptive pills (COCPs) stimulate hepatic synthesis of sex hormone-binding globulin (SHBG) primarily through their estrogenic component (ethinylestradiol). Elevated SHBG binds circulating free testosterone, decreasing bioavailable androgens and effectively improving clinical hyperandrogenic symptoms such as acne, hirsutism, and menstrual irregularity in women with polycystic ovary syndrome (PCOS). This mechanism and its clinical efficacy are well-established and form the basis of international clinical guideline recommendations for first-line management of PCOS.

1:04:27Thaïs Aliabadisupportedhigh

Slynd is a progestin-only birth control pill that is anti-androgenic.

"there's a progesterone-only birth control pill now called Slynd that helps with—it's very anti-androgenic, that I try for PCOS patients who need a method of birth control." (said at 1:04:27)

Slynd is a progestin-only oral contraceptive containing 4 mg drospirenone in a 24/4 regimen. Drospirenone is a synthetic progestin derived from spironolactone that exhibits distinct anti-androgenic and anti-mineralocorticoid properties, making it an established option for contraception and managing hyperandrogenic symptoms (such as acne and hirsutism) in women with polycystic ovary syndrome (PCOS), particularly those who cannot use estrogen-containing combined oral contraceptives.

1:05:23Thaïs Aliabadisupportedhigh

Lowering insulin levels reduces visceral fat, systemic inflammation, and ovarian androgen secretion.

"You have to lower that insulin, because if you lower that insulin, you're lowering visceral fat. You're lowering inflammation. You're lowering the ovaries from secreting androgens, right?" (said at 1:05:23)

The speaker's statement accurately reflects the well-established endocrinological pathophysiology linking hyperinsulinemia, adipose tissue dysfunction, systemic inflammation, and ovarian androgen synthesis (notably in conditions such as polycystic ovary syndrome). Insulin directly stimulates ovarian theca cell steroidogenesis and androgen production, while compensatory hyperinsulinemia and insulin resistance promote visceral adiposity and chronic low-grade inflammation (e.g., elevated TNF-alpha, IL-6). Lowering insulin levels via lifestyle changes, weight reduction, or insulin-sensitizing therapies directly decreases ovarian androgen secretion, reduces visceral adiposity, and attenuates systemic inflammation.

1:07:35Thaïs Aliabadisupportedmoderate

Inositol supplementation increases insulin sensitivity in patients with PCOS.

"I'm sure you've heard of inositol, different forms of inositol that work to increase sensitivity to insulin. And that's why these patients, when they take it, they say, "Oh, my periods became regular," or, "I took it and I got pregnant," because it does address that when it comes to this insulin resistance." (said at 1:07:35)

Multiple systematic reviews and meta-analyses of randomized controlled trials demonstrate that inositol supplementation (most commonly myo-inositol and D-chiro-inositol) improves insulin sensitivity, significantly reducing fasting insulin, area-under-the-curve (AUC) insulin, and homeostatic model assessment of insulin resistance (HOMA-IR) in women with PCOS. Furthermore, clinical trials confirm associated improvements in menstrual cyclicity, ovulation, and pregnancy rates compared to placebo.

1:11:32Thaïs Aliabadisupportedhigh

GLP-1 receptor agonists stimulate insulin secretion upon eating to clear glucose from the blood and improve insulin sensitivity.

"What GLP-1s do—people think it's an appetite suppressant and that's how it works. Well, that's a side effect of it. But what it does, it actually regulates that insulin. So when you eat, it spikes your insulin up and clears that sugar out of your blood, right?... Right, and it also makes you insulin sensitive." (said at 1:11:32)

The speaker accurately summarizes the established mechanisms of glucagon-like peptide-1 (GLP-1) receptor agonists. As incretin mimetics, GLP-1 receptor agonists stimulate glucose-dependent insulin secretion from pancreatic beta cells in response to nutrient ingestion, suppress glucagon secretion to clear postprandial glucose, and improve insulin sensitivity in peripheral tissues (both directly and secondary to weight loss and reduced glucotoxicity).

1:19:28Thaïs Aliabadisupportedhigh

With letrozole treatment, approximately 60 to 70 percent of PCOS patients ovulate, which is higher than the ovulation rate with Clomid (clomiphene).

"With letrozole, 60–70% of them I think ovulate, and with Clomid, it's a little bit less." (said at 1:19:28)

The speaker's statement accurately reflects the evidence from large randomized controlled trials. In the landmark PPCOS II trial (a double-blind multicenter RCT published in the New England Journal of Medicine, n=750), the cumulative ovulation rate among women with PCOS was 61.7% (834/1352 cycles) with letrozole compared to 48.3% (688/1425 cycles) with clomiphene citrate (P < 0.001).

1:23:17Andrew Huberman (host)supportedmoderate

Published scientific literature suggests that coenzyme Q10 and L-carnitine improve oocyte quality.

"I've seen a few papers um that suggest that coenzyme Q10 and L-carnitine might be beneficial for egg quality. [1:24:57] GUEST1: Yes." (said at 1:23:17)

The speaker cautiously states that published papers suggest coenzyme Q10 (CoQ10) and L-carnitine might benefit egg (oocyte) quality. Published literature and clinical trials support this claim. Systematic reviews and randomized trials show that CoQ10 improves mitochondrial function, oocyte retrieval numbers, and embryo quality in women undergoing assisted reproductive technology (especially in women with diminished ovarian reserve or ovarian aging). L-carnitine is also widely documented in animal and clinical reproductive literature to reduce oxidative stress, support mitochondrial fatty acid beta-oxidation, and enhance oocyte quality and developmental competence.

1:13:35Thaïs Aliabadisupportedhigh

A hemoglobin A1c of 5.7% is the diagnostic threshold for prediabetes.

"Let's say perimenopausal women with hemoglobin A1c in the borderline range, you know, 5.7, you fall into the prediabetic range." (said at 1:13:35)

The claim is supported. According to the American Diabetes Association (ADA) clinical practice guidelines, an HbA1c value between 5.7% and 6.4% (39–47 mmol/mol) defines the prediabetic (intermediate hyperglycemia) range. While some international guidelines (such as WHO and IEC) use a higher threshold of 6.0% to 6.4%, 5.7% is the widely utilized standard cutoff defining entry into the prediabetic range.

1:22:57Thaïs Aliabadisupportedmoderate

Women with PCOS typically exhibit a high ovarian reserve (follicle count) but have reduced oocyte quality.

"because PCOS patients, again, have tons of eggs, but the quality is not that good." (said at 1:22:57)

Polycystic ovary syndrome (PCOS) is clinically characterized by high antral follicle counts and elevated anti-Müllerian hormone (AMH) levels, reflecting a large ovarian reserve and yielding a high number of retrieved oocytes during assisted reproduction. However, endocrine and follicular microenvironment abnormalities (such as granulosa cell dysfunction, androgen excess, and altered signaling) impair follicle development and reduce oocyte competence/quality, resulting in lower fertilization rates and reduced per-oocyte reproductive outcomes despite high egg yields.

1:36:14Thaïs Aliabadisupportedmoderate

Endometriosis officially affects approximately 10% of women.

"Devastating, devastating condition that affects, you know, they say 10%; I think it's north of 20% because they're not diagnosed." (said at 1:36:14)

Epidemiological data and major global health guidelines widely report that endometriosis affects approximately 10% (typically cited as 5–10% or ~10%) of women and girls of reproductive age globally. The speaker correctly cites this standard recognized figure ('they say 10%') while offering personal clinical speculation on potential underdiagnosis.

1:38:35Thaïs Aliabadisupportedhigh

There is currently no blood test available to diagnose endometriosis.

"You do not need a fancy blood test. There's no blood test for endometriosis." (said at 1:38:35)

The speaker accurately states that there is currently no validated blood test available in routine clinical practice to diagnose endometriosis. Definitive diagnosis still relies primarily on surgical visualisation via laparoscopy (ideally with histological confirmation) or specialised imaging (e.g., transvaginal ultrasound or MRI for deep infiltrating endometriosis/endometriomas). Extensive systematic reviews evaluating over a hundred investigated blood biomarkers (such as CA-125, inflammatory cytokines, and microRNAs) have concluded that none demonstrate sufficient sensitivity and specificity to serve as a diagnostic replacement for standard clinical workups.

1:44:05Andrew Huberman (host)supportedhigh

About 10 years ago, scientific grant funding bodies established a requirement that funded preclinical biomedical research must evaluate both sexes rather than only male animals.

"and we know that the in the research community it started about 10 years back there was a requirement actually to get grants funded that um that people evaluate both sexes. So believe it or not, it was all done on male mice for large largely male uh done." (said at 1:44:05)

The host's statement accurately reflects major policy developments in biomedical research funding. In 2015, the National Institutes of Health (NIH) introduced the 'Sex as a Biological Variable' (SABV) policy (implemented for grant applications starting in January 2016), which required researchers applying for funding to account for sex as a biological variable in vertebrate animal and human studies. Similar policies were implemented around the same time by international funding agencies, such as the Canadian Institutes of Health Research (CIHR) and the European Commission, directly addressing the historical overreliance on male animals and tissues in preclinical research.

1:48:38Thaïs Aliabadisupportedmoderate

Ectopic endometriosis implants produce their own local estrogen.

"So they start making their own estrogen, right? So locally they support themselves without needing systemic estrogen. Right." (said at 1:48:38)

Extensive molecular and tissue-level research confirms that endometriotic implants express steroidogenic enzymes—including aromatase (CYP19A1), steroid sulfatase (STS), and 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1)—while exhibiting deficient 17β-HSD type 2 (which normally inactivates estradiol). This enables ectopic endometriotic lesions to synthesize 17β-estradiol locally and create an autonomous, hyperestrogenic microenvironment that promotes their own survival and progression independently of circulating systemic estrogen levels.

1:48:50Thaïs Aliabadisupportedmoderate

Endometriotic lesions develop increased vascularity and grow nerve fibers around each lesion.

"And then they start, you know, they increase vascularity to the lesion and then they start um growing nerve uh fibers around each lesion." (said at 1:48:50)

Extensive histological and mechanistic evidence demonstrates that endometriotic lesions recruit their own vascular and neural supply through coordinated angiogenesis and neurogenesis (termed neuroangiogenesis). Systematic reviews and tissue studies show that endometriotic implants and their surrounding microenvironment exhibit increased vascularization and increased nerve fiber density (including sensory and autonomic fibers) driven by angiogenic factors and neurotrophins such as NGF and BDNF.

1:49:58Thaïs Aliabadisupportedmoderate

The average age of diagnosis for endometriosis is 32 years old.

"that's why these patients average age of diagnosis for endometriosis is 32 and it takes doctors 9 to 11 years to diagnose these patients" (said at 1:49:58)

Epidemiological studies and systematic reviews consistently demonstrate significant diagnostic delays in endometriosis, with delays commonly spanning up to 7–12 years between symptom onset and definitive diagnosis, and mean age at diagnosis frequently falling in the early thirties (around 30–32 years). Systematic reviews identify substantial contributions from both provider- and patient-level barriers to timely diagnosis.

1:52:10Thaïs Aliabadisupportedhigh

The presence of an endometrioma (chocolate cyst) in an ovary categorizes a patient as approximately stage 3 out of 4 endometriosis.

"Not that you can diagnose endometriosis on ultrasound, but if you have an endometrioma or a chocolate cyst, which takes you to approximately a stage three out of four endometriosis, you can see it in two seconds on ultrasound." (said at 1:52:10)

Under the widely utilized revised American Society for Reproductive Medicine (rASRM) 4-stage classification system (Stage I: Minimal [1–5], Stage II: Mild [6–15], Stage III: Moderate [16–40], Stage IV: Severe [>40]), deep ovarian endometriosis/endometriomas are heavily weighted. A deep ovarian endometrioma of 1–3 cm scores 16 points and >3 cm scores 20 points, which automatically categorizes the condition as at least Stage III (moderate) endometriosis (or Stage IV if bilateral or associated with extensive adhesions).

1:53:45Thaïs Aliabadisupportedhigh

Adenomyosis is characterized by ectopic endometrial tissue growing within the muscular wall of the uterus.

"and adenomyosis is when these ectopic tissue the uh lining inside the uterus are in the wall of the uterus." (said at 1:53:45)

The speaker's statement accurately reflects the standard histopathological definition of adenomyosis. Published literature and consensus guidelines consistently define adenomyosis as a benign condition in which ectopic endometrial tissue (glands and/or stroma that normally form the inner lining of the uterus) is found within the myometrium (the muscular uterine wall).

1:53:33Thaïs Aliabadisupportedmoderate

Endometriosis and associated pelvic inflammation increase the risk of ectopic pregnancy and miscarriage.

"The embryo sometimes doesn't form. If it forms, it might get stuck in the tube and you might end up with an ectopic pregnancy or if it goes into the uterus, all that inflammation increases the risk of miscarriage." (said at 1:53:33)

Systematic reviews and meta-analyses support the association between endometriosis and an increased risk of both ectopic pregnancy and miscarriage. A meta-analysis of 15 observational studies found an elevated risk of ectopic pregnancy in women with endometriosis (case-control OR = 2.66; higher-quality cohort OR = 2.16). Similarly, large meta-analyses demonstrate a significantly increased risk of miscarriage in women with endometriosis, particularly in spontaneous conceptions (OR = 1.30 to 1.81).

2:01:08Thaïs Aliabadisupportedmoderate

Endometriosis-associated chronic pelvic pain involves central sensitization triggered by nerve fibers growing into endometriotic lesions.

"And what happens eventually these nerve fibers start shooting and our central nervous system starts going in overdrive and exaggerating those pains. That's why the pain is so real and so debilitating because their body they get sensitization to this new nerve pains that are forming in their pelvis." (said at 2:01:08)

The speaker accurately describes the established pathophysiological mechanisms underlying endometriosis-associated chronic pelvic pain. Published evidence demonstrates that neurogenesis and altered nerve fiber innervation (neuroangiogenesis) occur within and around endometriotic lesions. Chronic stimulation and inflammatory signaling from these peripheral nerve fibers lead to peripheral sensitization and subsequent central sensitization (the central nervous system becoming hyper-responsive to pain signals).

1:46:45Thaïs Aliabadisupportedhigh

The retrograde menstruation hypothesis proposes that menstrual fluid containing endometrial tissue flows backward through the fallopian tubes into the pelvic cavity and implants on pelvic structures.

"The most common one is probably retrograde menstruation, which a lot of women uh get, which means when we're having our period, some of that blood goes through the tubes and out into the pelvis and implants there." (said at 1:46:45)

The speaker accurately describes Sampson's classic hypothesis of retrograde menstruation, which proposes that during menstruation, shed menstrual blood containing viable endometrial fragments flows backward through the fallopian tubes into the peritoneal/pelvic cavity, where it adheres and implants on pelvic organs and peritoneal surfaces.

2:02:03Andrew Huberman (host)supportedhigh

Peripheral nerves readily regenerate after injury, unlike central nervous system tissue following brain injury.

"Peripheral nerves grow back very readily once they're there. I mean, this is reassuring to anyone that has a peripheral nerve injury, it'll grow back, unlike a brain injury where it's variable outcome." (said at 2:02:03)

The host's statement accurately reflects a fundamental neurobiological principle: axons in the peripheral nervous system (PNS) possess intrinsic regenerative capacity and are supported by a permissive environment (including reprogrammed repair Schwann cells and macrophage-mediated clearance of myelin debris during Wallerian degeneration). In contrast, central nervous system (CNS) tissue (such as the brain and spinal cord) has extremely limited regenerative capacity due to intrinsic neuronal limitations, glial scar formation, and myelin-associated inhibitory molecules.

2:08:36Thaïs Aliabadisupportedhigh

Endometriosis implants grow in response to estrogen, and their growth slows down in response to progesterone.

"endometriosis implants in general, not the stromal type, they grow with estrogen, but their growth slows down with progesterone." (said at 2:08:36)

The speaker's statement accurately reflects the fundamental hormonal biology and pharmacology of endometriosis. Endometriosis is well-established as an estrogen-dependent disease where estrogen drives ectopic endometrial cell proliferation, angiogenesis, and lesion growth. Conversely, progesterone and progestins act as antiproliferative agents that counteract estrogenic stimulation, induce atrophy of ectopic endometrial tissue, and slow or arrest lesion growth, which forms the basis for progestin-based medical therapy being first-line clinical management.

2:10:08Thaïs Aliabadisupportedhigh

The Mirena levonorgestrel intrauterine device lasts for up to eight years for contraception and five years for heavy menstrual bleeding.

"Mirena IUD is the most common progesterone IUD used in this country. If you use it for—it's a method of birth control and it can last for eight years. Sometimes we use it for heavy period and you use it for five years." (said at 2:10:08)

Clinical trial data from the Mirena Extension Trial demonstrated that the 52-mg levonorgestrel-releasing intrauterine system (Mirena) maintains high contraceptive efficacy through 8 years of use, leading to regulatory approval for up to 8 years for contraception. The trial noted that data did not evaluate extended use beyond 5 years specifically for heavy menstrual bleeding, for which its approved duration of use remains up to 5 years.

2:10:27Thaïs Aliabadisupportedhigh

The Kyleena intrauterine device is physically smaller in size than the Mirena intrauterine device.

"For young girls who haven't had children, I tend to go with the smaller IUD because Mirena IUD is slightly larger than the Kyleena IUD." (said at 2:10:27)

Kyleena (LNG-IUS 12 / LNG-IUS 19.5 mg) is manufactured on a smaller T-body frame (28 mm × 30 mm, with a narrower inserter tube diameter of 3.8 mm) compared to Mirena (LNG-IUS 20 / 52 mg; 32 mm × 32 mm frame, 4.4 mm inserter tube diameter). Published reviews confirm that Kyleena has a smaller physical frame and narrower insertion tube compared to LNG-IUS 20 (Mirena).

2:11:27Thaïs Aliabadisupportedhigh

GnRH antagonist medications like Orilissa and Myfembree can only be taken for up to two years because of the risk of bone mineral density loss.

"The problem with these pills are because of the effect on the bone and the bone loss it causes, you can take them up to two years. So you can't take them beyond two years." (said at 2:11:27)

Oral GnRH antagonists (such as elagolix [Orilissa] and relugolix combination therapy [Myfembree]) induce a hypoestrogenic state that causes progressive bone mineral density (BMD) loss. In regulatory approvals and phase III trial evidence, treatment duration is strictly capped at a maximum of 24 months (2 years) specifically to mitigate the risk of irreversible bone mineral density loss (with higher elagolix doses capped even earlier at 6 months).

2:12:20Thaïs Aliabadisupportedmoderate

The surgical or anatomical stage of endometriosis does not correlate with the severity of pelvic pain experienced by the patient.

"the stage of endometriosis has nothing to do with the degree of pain. And this is very important for patients to understand. You can have stage one endometriosis and you end up in the emergency room every month because of pain, or you can have stage four endometriosis and you just have mild pain." (said at 2:12:20)

The claim is supported by clinical literature and meta-analyses. The widely used revised American Society for Reproductive Medicine (rASRM) staging system assesses anatomical disease extent and adhesions, but multiple systematic reviews and observational studies confirm that overall pain intensity does not correlate with the surgical stage (e.g., severe debilitating pain can occur in stage I disease, whereas extensive stage IV disease may present with mild symptoms). Anatomical location (such as deep infiltrating endometriosis mapped by systems like #Enzian) better explains specific organ-related pain symptoms than overall rASRM stage.

2:17:23Thaïs Aliabadisupportedhigh

The average age of natural menopause is 51.5 years, typically occurring between ages 45 and 55.

"Average age of menopause is 51 and a half, 45 to 55 is the range." (said at 2:17:23)

Large-scale prospective and epidemiological cohort studies show that the median/mean age of natural menopause in industrialized nations is approximately 51 to 51.5 years (e.g., 51.3 to 51.4 years in landmark studies like the Massachusetts Women's Health Study and SWAN), with the typical normal range spanning ages 45 to 55 (menopause before 45 is categorized as early/premature).

2:18:24Thaïs Aliabadisupportedmoderate

Approximately 80 percent of women will develop uterine fibroids by age 50.

"Fibroids are very common. By age 50, 80% of women have some form of fibroids." (said at 2:18:24)

Epidemiological and ultrasound-screening data demonstrate that uterine fibroids (leiomyomas) are extremely common, with an estimated cumulative incidence of 70% to >80% by age 50. In the landmark NIEHS uterine fibroid study (Baird et al., 2003), ultrasound screening and medical record review revealed an estimated cumulative incidence of tumors by age 50 of >80% for Black women and nearly 70% for White women. Systematic reviews of the evidence confirm a cumulative incidence by age 50 of approximately 70% to 80%.

2:06:51Thaïs Aliabadisupportedmoderate

Endometriosis implants can occur in extra-pelvic anatomical sites, including the diaphragm, lungs, and brain.

"That's why we see implants sometimes by the diaphragm or so you can find it in people's lungs or very rarely in their brain." (said at 2:06:51)

Extrapelvic endometriosis is well-documented in the medical literature. Systematic reviews of extrapelvic endometriosis confirm that endometrial implants can occur in the diaphragm, pleural/pulmonary parenchyma (lungs), and, extremely rarely, the central nervous system/brain.

2:25:40Thaïs Aliabadisupportedhigh

A history of anxiety, PTSD, depression, or premenstrual dysphoric disorder increases the risk of developing postpartum depression.

"So anyone with any history of anxiety, PTSD, or depression or PMDD, a severe form of PMS, all of these patients are at a higher risk of postpartum depression." (said at 2:25:40)

Extensive meta-analytic and large nationwide population-based cohort evidence confirms that a personal psychiatric history of depression, anxiety, trauma/PTSD, or premenstrual dysphoric disorder (PMDD) significantly increases the risk of developing postpartum depression (PPD). Meta-analyses identify a history of depression (OR ~3.1) and anxiety as key predictors of PPD. Additionally, systematic reviews and nationwide cohort studies show that women with premenstrual disorders have a substantially elevated risk of developing perinatal depression (adjusted OR ~2.7).

2:33:16Thaïs Aliabadisupportedmoderate

A uterine septum causes recurrent miscarriages and infertility.

"Unless you do a pelvic ultrasound and unless you're a good ultrasonographer, you will miss this septum. And these are patients who have recurrent miscarriages. They don't get pregnant." (said at 2:33:16)

A septate uterus is well documented in systematic reviews and meta-analyses to be significantly associated with recurrent pregnancy loss (miscarriage) and reduced fertility (lower pregnancy rates). A meta-analysis of observational studies found that women with an untreated uterine septum had significantly lower pregnancy rates (OR 0.45, 95% CI 0.27–0.76) and more than four times higher odds of spontaneous abortion (OR 4.29, 95% CI 2.90–6.36) compared to controls without a septum. Systematic reviews of uterine anomalies also identify septate uterus as the most common congenital anomaly found in populations presenting with recurrent miscarriage and infertility.

2:34:50Thaïs Aliabadisupportedmoderate

Women with PCOS and symptoms of elevated testosterone have a 70% to 80% chance of anovulation.

"Do you have symptoms of high testosterone? If you do, you're 70, 80% chance you're not even ovulating." (said at 2:34:50)

In women diagnosed with polycystic ovary syndrome (PCOS) who present with clinical or biochemical hyperandrogenism (elevated testosterone/androgens), approximately 70% to 80% have chronic anovulation or oligo-ovulation (corresponding to Rotterdam phenotypes A and B, or 'classic PCOS'). The remaining 20% to 30% of hyperandrogenic women with PCOS have ovulatory PCOS (phenotype C, characterized by hyperandrogenism and polycystic ovarian morphology with regular ovulatory cycles).

2:35:16Thaïs Aliabadisupportedmoderate

Having one diagnosed autoimmune condition confers approximately a 30% chance of developing another autoimmune condition.

"if you have one autoimmune condition, you probably have a 30% chance of having some other autoimmune condition." (said at 2:35:16)

Observational cohort studies across several index autoimmune diseases consistently report that approximately 25% to 38% (roughly one-third) of individuals with an autoimmune disorder develop or exhibit co-occurring polyautoimmunity (a second diagnosed autoimmune condition), closely matching the speaker's estimate.

2:35:24Thaïs Aliabadisupportedhigh

Antiphospholipid syndrome is a hypercoagulable state that during pregnancy can cause placental blood clots and recurrent miscarriages.

"because if someone has, let's say, antiphospholipid syndrome and they're hypercoagulable, and pregnancy makes you more hypercoagulable, you can actually make blood clots in the placenta, and these are patients who keep having miscarriages and they don't know why." (said at 2:35:24)

Antiphospholipid syndrome (APS) is a well-established autoimmune, hypercoagulable disorder characterized by vascular thrombosis and pregnancy complications. In obstetric APS, the presence of antiphospholipid antibodies—exacerbated by the hypercoagulable state of pregnancy—contributes to placental thrombosis, placental insufficiency, and recurrent pregnancy loss (miscarriages). It is one of the most recognized and treatable causes of recurrent pregnancy loss.

2:38:51Thaïs Aliabadisupportedhigh

The average lifetime risk of developing breast cancer for an American woman is approximately 12.5%.

"An average American has a 12.5% chance of getting breast cancer. HOST: 12.5%. GUEST1: Average American. HOST: For women specifically. GUEST1: Yes." (said at 2:38:51)

Standard epidemiological data for the United States (such as from the National Cancer Institute's SEER registry) estimate that an American woman has approximately a 1 in 8, or about 12.5% to 13%, lifetime risk of being diagnosed with breast cancer.

2:39:28Thaïs Aliabadisupportedhigh

Breast cancer risk models categorize low risk as less than 15%, intermediate risk as 15% to 20%, and high risk as 20% or greater lifetime risk.

"Again, there are three buckets for breast cancer risk: low risk is less than 15%, intermediate risk is 15 to 20%, and high risk is 20% or more." (said at 2:39:28)

Standard breast cancer risk stratification guidelines and clinical risk assessment models categorize lifetime breast cancer risk into three main tiers: average/low risk (<15% lifetime risk), intermediate risk (15% to 20% lifetime risk), and high risk (≥20% lifetime risk, which typically qualifies individuals for supplemental screening such as breast MRI under guidelines from the American Cancer Society and other organizations).

2:40:35Thaïs Aliabadisupportedmoderate

Having children after age 30 or not having children increases a woman's lifetime risk of breast cancer.

"Patients who have children after age 30 are at a higher risk, women who haven't had children, women with family history, women with genetic mutations." (said at 2:40:35)

Epidemiological cohort evidence confirms that nulliparity (not having children) and older age at first childbirth (such as after age 30) are established risk factors that increase a woman's lifetime risk of developing breast cancer, particularly estrogen receptor-positive (ER+) breast cancer, the predominant subtype. In large cohort studies including the Million Women Study (over 1.2 million women), age at first birth is positively associated with risk, whereas parity is inversely associated with risk.

2:44:28Thaïs Aliabadisupportedhigh

Tamoxifen reduces the risk of developing breast cancer by 50% over the subsequent 10 years in high-risk women.

"or asking their doctor for a medication called tamoxifen, HOST: Estrogen receptor blocker. GUEST1: that reduces the risk of breast cancer by 50% in the next 10 years of their life" (said at 2:44:28)

Large randomized controlled trials and individual participant data meta-analyses confirm that 5 years of tamoxifen chemoprevention reduces the risk of breast cancer by approximately 40% to 50% (primarily driven by a ~50% reduction in estrogen receptor-positive disease) over a 10-year follow-up period in women at increased risk. Landmark trials such as the NSABP P-1 trial demonstrated a 49% reduction in invasive breast cancer incidence, and a 2013 meta-analysis of over 83,000 women across 9 SERM prevention trials documented a 38% overall reduction in all breast cancer incidence over 10 years (42% in the first 5 years).

2:44:45Thaïs Aliabadisupportedhigh

Approximately 85% of women who develop breast cancer have no family history of the disease.

"85% of women who get breast cancer don't have it in their family." (said at 2:44:45)

The speaker's statement that approximately 85% of women who develop breast cancer do not have a family history of the disease accurately reflects established epidemiological data. Large population-based studies and cancer surveillance data (including from the American Cancer Society, CDC, and the Collaborative Group on Hormonal Factors in Breast Cancer) establish that approximately 85% to 87% of breast cancer diagnoses are sporadic—occurring in women without an affected first-degree relative. Only about 13% to 15% of women diagnosed have a family history, and only 5% to 10% are attributable to known hereditary high-penetrance germline mutations (such as BRCA1/BRCA2).

2:44:50Thaïs Aliabadisupportedhigh

Fewer than 5% of women who get breast cancer carry an identified cancer-causing genetic mutation.

"Less than 5% have a genetic mutation." (said at 2:44:50)

Large population-based studies and routine testing cohorts of unselected women with breast cancer consistently show that approximately 4.5% to 5% carry an identified pathogenic germline mutation in established breast cancer susceptibility genes. For example, a prospective NHS study of 3,515 unselected breast cancer patients identified germline pathogenic variants in 4.7% of cases across seven major susceptibility genes (BRCA1, BRCA2, PALB2, CHEK2, ATM, RAD51C, and RAD51D). Similarly, large population-based meta-analyses of over 100,000 unselected breast cancer cases show that pathogenic variants in high- and moderate-penetrance genes together occur in roughly 4% to 5% of patients.

2:54:28Thaïs Aliabadisupportedmoderate

Premenstrual dysphoric disorder (PMDD) symptoms typically onset 10 days before menstruation and resolve 2 to 3 days after menstruation starts.

"So PMDD, the symptoms usually start 10 days before the period and goes away two, three days after the period." (said at 2:54:28)

Standard diagnostic criteria (DSM-IV/DSM-5) and prospective symptom-tracking studies define PMDD by symptoms that emerge during the late luteal phase (typically the 7 to 10 days before menses), peak shortly before menstruation, and remit within a few days following the onset of menses.

2:54:55Thaïs Aliabadisupportedmoderate

Luteal-phase dosing of SSRIs (such as 20 mg fluoxetine or 25 mg sertraline taken for 10 to 14 days before menses) is effective for treating PMDD.

"For these patients, you can prescribe 20 milligrams of Prozac 10 to 14 days before their period. So they only take it 10 to 14 days per month after ovulation. They start taking it once a day, and they stop at the onset of their period. You can also treat them with 25 milligrams of Zoloft." (said at 2:54:55)

A 2024 Cochrane systematic review and meta-analysis of 34 randomized controlled trials evaluated SSRIs (including fluoxetine and sertraline) for PMS and PMDD. The review confirmed that luteal-phase intermittent dosing significantly reduces overall premenstrual symptoms compared to placebo (SMD -0.39, 95% CI -0.58 to -0.21; 6 studies, 687 participants; moderate-certainty evidence). While continuous daily dosing showed a slightly larger effect size (SMD -0.69), intermittent luteal-phase dosing (starting after ovulation and stopping at menses) remains an established and effective treatment strategy.

2:59:22Thaïs Aliabadisupportedmoderate

Endometriosis carries a slightly increased risk of ovarian cancer, particularly in patients with endometriomas or advanced disease.

"So, endometriosis patients in general have a slightly higher increased risk of ovarian cancer, especially the ones with endometriomas or advanced disease." (said at 2:59:22)

Epidemiological studies and systematic reviews consistently demonstrate that women with endometriosis have a slightly increased relative risk of epithelial ovarian cancer (particularly endometrioid and clear cell subtypes), while the absolute lifetime risk remains low. Risk is substantially more elevated in women with ovarian endometriomas, deep infiltrating endometriosis, or advanced disease.

  • supports: Endometriosis Typology and Ovarian Cancer Risk. (JAMA 2024) · cited 153x in the literature
    "Ovarian cancer risk was higher among women with endometriosis compared with women without endometriosis (aHR, 4.20 [95% CI, 3.59-4.91]; aRD, 9.90 [95% CI, 7.22-12.57])... Ovarian cancer risk was highest in women with deep infiltrating endometriosis and/or ovarian endometriomas for all ovarian cancers (aHR, 9.66 [95% CI, 7.77-12.00]; aRD, 26.71 [95% CI, 20.01-33.41])" (abstract, results)
    pubmedfull study (doi)
  • supports: Endometriosis and ovarian cancer risk. (Gynecologic oncology 2026)
    "Epidemiological studies consistently demonstrate a modest but statistically significant increase in ovarian cancer risk among women with endometriosis, particularly for endometrioid and clear cell subtypes. Cohort studies report relative risks ranging from 1.3 to 4.2, with the highest estimates observed in women with ovarian endometriomas or deep infiltrating disease." (abstract, results, passage verified)
    pubmedfull study (doi)
2:59:55Thaïs Aliabadisupportedmoderate

Postmenopausal estrogen replacement therapy without progesterone can reactivate residual endometriotic implants in patients with a history of endometriosis even after hysterectomy.

"In patients with endometriosis, even when they undergo a hysterectomy and they're using estrogen patches, you always want to give them the progesterone because otherwise you stimulate these implants again because of unopposed estrogen." (said at 2:59:55)

Clinical practice guidelines and reviews consistently support the recommendation that patients with a history of endometriosis who undergo a hysterectomy should receive combined estrogen-progestogen menopausal hormone therapy (or tibolone) rather than estrogen-only therapy. Unopposed estrogen therapy can stimulate and reactivate residual endometriotic lesions/implants and increases the risk of disease recurrence and malignant transformation.

2:40:14Thaïs Aliabadisupportedhigh

Higher breast tissue density is associated with an increased lifetime risk of developing breast cancer.

"The higher the density, the higher your lifetime risk of breast cancer." (said at 2:40:14)

Higher mammographic breast density is a well-established, independent risk factor for developing breast cancer. Meta-analyses demonstrate a clear dose-response relationship: women with the highest percentage of dense tissue (e.g., >=75%) have a 4- to 5-fold higher relative risk of developing breast cancer compared with women with low density (<5%), and each standard deviation increase in percentage dense area is associated with an approximate 50% increase in breast cancer risk across both premenopausal and postmenopausal populations.

2:38:58Thaïs Aliabadisupportedmoderate

A breast biopsy showing atypia significantly increases a woman's lifetime risk of developing breast cancer.

"Now, the problem is if you have family history of breast cancer, or if you have a biopsy that shows atypia at some point in your life, that will significantly increase your lifetime risk of breast cancer." (said at 2:38:58)

Large cohort studies (such as the Mayo Clinic and Nashville benign breast disease cohorts) demonstrate that identifying atypia (atypical ductal hyperplasia or atypical lobular hyperplasia) on a breast biopsy substantially increases subsequent breast cancer risk. Relative risk is increased approximately 3- to 5-fold (or higher with multiple foci), conferring an absolute long-term risk of developing breast cancer that can approach 25% to 30% over 25 years.

2:53:10Thaïs Aliabadisupportedmoderate

Inositol supplementation is effective for managing polycystic ovary syndrome (PCOS).

"Is inositol useful for PCOS? GUEST1: Yes, absolutely." (said at 2:53:10)

Multiple systematic reviews and meta-analyses of randomized controlled trials demonstrate that inositol supplementation (particularly myo-inositol) improves key clinical and biochemical features of polycystic ovary syndrome (PCOS). Specifically, it significantly improves menstrual cycle regularity, ovulation and pregnancy rates, insulin resistance markers (HOMA-IR, fasting insulin), and hyperandrogenism markers (total and free testosterone, SHBG) compared to placebo, showing comparable efficacy to metformin with fewer gastrointestinal side effects.

3:01:24Thaïs Aliabadisupportedmoderate

Women develop increased insulin resistance as they approach menopause, regardless of whether they have PCOS.

"As we get closer to menopause, we become more insulin resistant regardless of whether we had PCOS or not." (said at 3:01:24)

The claim is supported by longitudinal cohort studies and metabolic reviews. During the menopausal transition (perimenopause), declining estradiol levels and associated changes in body composition (such as visceral fat accumulation and loss of lean mass) lead to an increase in insulin resistance and a decline in insulin sensitivity. This normative physiological transition occurs across the general population of midlife women, independent of whether they have pre-existing endocrine conditions such as polycystic ovary syndrome (PCOS).

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.